Trinity Biotech
TRIB
28 hedge funds and large institutions have $2.81M invested in Trinity Biotech in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
176% more call options, than puts
Call options by funds: $58K | Put options by funds: $21K
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
69% more capital invested
Capital invested by funds: $1.66M → $2.81M (+$1.14M)
12% more funds holding
Funds holding: 25 → 28 (+3)
6.33% more ownership
Funds ownership: 113.33% → 119.67% (+6.3%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$120K |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$51.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$41.4K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$28.6K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$13.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Whitefort Capital Management
New York
|
-$53.2K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17.1K |
| 3 |
WN
Williams & Novak
Westlake Village,
California
|
-$10.5K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$5.29K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$1.14K |
TRIB Hedge Fund Activity: Q3 2025 in Review
28 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2025, worth a combined $2.81M — up 69% from $1.66M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TRIB positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $120K. The largest seller was Whitefort Capital Management, exiting entirely with an estimated $53.2K sold.
- 28 institutional investors held Trinity Biotech (TRIB) as of Q3 2025, up from 25 in Q2 2025.
- Funds reported $2.81M of Trinity Biotech stock for Q3 2025, up 69% quarter-over-quarter.
- 7 funds opened new Trinity Biotech positions in Q3 2025 and 4 closed out, a net change of +3 holders.
- The largest Trinity Biotech buyer in Q3 2025 was Renaissance Technologies, an estimated $120K added.
- The largest Trinity Biotech seller in Q3 2025 was Whitefort Capital Management, an estimated $53.2K sold.
Based on aggregated 13F filings for Q3 2025.